Merck
Merck and Incyte to initiate Keytruda, epacadostat combo trial
October 15, 2015Research and Development Incyte, Merck, R&D, melanoma, phase III, skin cancer
Merck and biopharma firm Incyte are to expand their clinical collaboration to include a Phase III study evaluating the combination …
Merck rebrands as ‘science and technology’ company
October 14, 2015Medical Communications, Research and Development, Sales and Marketing Merck, Merck Millipore, Merck Serono, rebrand, restructure
Merck Group has rebranded to “reflect its transformation into a science and technology company”, and restructured its business to create …
Merck improves manufacturing program
October 13, 2015Manufacturing and Production Merck, Merck Millipore, manufacturing, production
Merck Millipore, the life science business arm of Merck KGaA, has introduced enhancements to its Emprove portfolio of raw pharmaceutical …
MSD’s Keytruda receives green light from NICE for NHS use
October 12, 2015Sales and Marketing MSD, Merck, NICE, keytruda, melanoma, pembrolizumab, skin cancer
The UK healthcare watchdog NICE has recommended Keytruda as a treatment for advanced skin cancer – its second endorsement of …
NICE approves Merck’s Keytruda for advanced skin cancer following ipilimumab treatment
October 7, 2015Research and Development Merck, NHS, NICE, keytruda, skin cancer
The National Institute for Health and Care Excellence (NICE) has approved Merck’s Keytruda (pembrolizumab) for treating advanced skin cancer after …
Merck and Wayra to tackle NHS funding gap with startup rewards programme
September 25, 2015Research and Development MSD, Merck
Merck Sharpe and Dohme (MSD) and Wayra Open Future, Telefonica’s digital start up accelerator, are investing in digital innovation in …
NICE recommends Keytruda for advanced skin cancer
September 7, 2015Research and Development, Sales and Marketing Merck, NICE, keytruda, skin cancer
NICE has approved Merck’s Keytruda (pembrolizumab) as a treatment for advanced skin cancer in final draft guidance for the NHS. …
Novartis and Merck skin cancer drugs move through pipeline
August 20, 2015Manufacturing and Production, Research and Development, Sales and Marketing Merck, Novartis, Odomzo, basal cell carcinoma, keytruda, melanoma, pembrolizumab, skin cancer, sonidegib
Both Novartis and Merck have hit regulatory milestones with their skin cancer drugs in the EU and the US. Novartis’ …
Merck in immuno-oncology collaboration with major cancer research centre
August 14, 2015Research and Development Cancer, Merck, keytruda, oncology
Merck is teaming up with the University of Texas to evaluate Merck’s anti-PD-1 therapy, Keytruda, in combination with other treatmentsA team …
David Khougazian announced as president of Sanofi Pasteur MSD
July 29, 2015Business Services, Research and Development, Sales and Marketing MSD, Merck, Sanofi Pasteur
Sanofi Pasteur and Merck have appointed David Khougazian as president of their joint company, Sanofi Pasteur MSD. David Khougazian joined …
EU approval for new Sanofi, Merck vaccine
June 18, 2015Sales and Marketing EU, Europe, Merck, Sanofi, Sanofi pasteur msd, brett wells, gardasil 9
Sanofi and Merck are looking forward to a successor to their blockbuster Gardasil now that the European Commission has granted …
Merck diabetes drug gets CV trial boost
June 9, 2015Research and Development, Sales and Marketing Januvia, Merck, cv, diabetes, sitagliptin
Merck’s diabetes drug Januvia has been given a boost following worries over side effects for patients after a trial revealed …
Merck launches new antibiotic in the UK
June 5, 2015Research and Development, Sales and Marketing AMR, Antibiotics, MSD, Merck, Sivextro, antimicrobial resistance, cubist, tedizolid phosphate
Merck has launched the first new drug in a class of antibiotics in the UK in almost 15 years, becoming …
Merck tests new Keytruda combination
June 3, 2015Research and Development, Sales and Marketing Merck, dynavax, keytruda
Merck is continuing to investigate Keytruda combinations as it signs a deal to test the drug with an immunotherapy from …
EMA recommends eight drugs for approval
May 22, 2015Sales and Marketing Amgen, BMS, EMA, Janssen, Merck, keytruda
The EMA has recommended eight medicines for approval in a round of reviews, including four new cancer indications. Amgen’s Repatha …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
